CRISPR Therapeutics AGOpportunity Rank #320(CRSP) Intrinsic Value & DCF Analysis (2026)
Current Price
$46.88
Last updated: Mar 24, 2026
Price vs Intrinsic Value
Fundamental Score
Weighted across 6 signals
Narrative Score
No change vs previous
The intrinsic value of CRISPR Therapeutics AG (CRSP) is estimated at $17.51 per share based on a 10-year discounted cash flow (DCF) analysis. At the current price of $46.88, the stock appears overvalued relative to its projected cash flow fundamentals. This estimate assumes a -60.04% long-term growth rate and a 10.83% discount rate, reflecting expected future free cash flow and cost of capital.
The intrinsic value of CRISPR Therapeutics AG (CRSP) is estimated at $17.51 per share based on a 10-year discounted cash flow (DCF) analysis. At the current price of $46.88, the stock appears overvalued relative to its projected cash flow fundamentals. This estimate assumes a -60.04% long-term growth rate and a 10.83% discount rate, reflecting expected future free cash flow and cost of capital.Valuation Details
Capital Efficiency
The company is earning below its required return. This may indicate inefficient use of capital or excess cash that isn't being reinvested.
Fundamental Details
Narrative Details
Investment Coach
- Price moving to at least a mid-teens discount to fair value
- Improvement in ROIC versus WACC spread
- Meaningful positive shifts in the company narrative and fundamental score
Free Cash Flow (in millions)
How Intrinziq Estimates Fair Value
Intrinziq estimates CRISPR Therapeutics AG's intrinsic value using a discounted cash flow (DCF) model based on free cash flow trends and a market-based discount rate. The model projects future cash flows over ten years and discounts them using a market return assumption to estimate fair value.
CRISPR Therapeutics AGHealthcare
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA. The company has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company's lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from transfusion-dependent beta-thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells. It also develops CTX110, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting cluster of differentiation 19 positive malignancies; CTX120, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting B-cell maturation antigen for the treatment of relapsed or refractory multiple myeloma; and CTX130, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting Cluster of Differentiation 70 to treat various solid tumors and hematologic malignancies. In addition, the company develops VCTX210, a gene-edited immune-evasive stem cell-derived product candidate for the treatment of treatment of type 1 diabetes; and pursues various in vivo gene-editing programs that target the liver, lung, muscle, and central nervous system diseases. It has strategic partnerships with Bayer Healthcare LLC, Vertex Pharmaceuticals Incorporated, ViaCyte, Inc., Nkarta, Inc., and Capsida Biotherapeutics. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland.